Alpha 2.0
Login Register
» Authors » M Kneba

M Kneba

Explore the profile of M Kneba including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 108
Citations 3658
Followers 0
Related Specialties
Oncology
Hematology
Pathology
Top 10 Co-Authors
G Krieger
I Bolz
W Hiddemann
G A Nagel
M Ritgen
M Bruggemann
P Dreger
M Hallek
S Bottcher
C Pott
Published In
Leukemia
Bone Marrow Transplant
Ann Hematol
Ann Oncol
Onkologie
Affiliations
Soon will be listed here.
Recent Articles
1.
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
Furstenau M, Bahlo J, Fink A, Lange E, Dreger P, Dreyling M, et al.
Leukemia . 2019 Oct; 34(3):924-928. PMID: 31611627
No abstract available.
2.
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
Schultheis B, Reuter D, Ebert M, Siveke J, Kerkhoff A, Berdel W, et al.
Ann Oncol . 2017 Sep; 28(10):2429-2435. PMID: 28961832
Background: This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with gem plus placebo as first-line...
3.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb H, et al.
Leukemia . 2017 Aug; 31(11):2398-2406. PMID: 28804124
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430)...
4.
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
Al-Sawaf O, Robrecht S, Bahlo J, Fink A, Cramer P, von Tresckow J, et al.
Leukemia . 2017 Jul; 31(10):2251-2253. PMID: 28745332
No abstract available.
5.
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
Sellner L, Bruggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, et al.
Bone Marrow Transplant . 2017 Apr; 52(4):656. PMID: 28377595
No abstract available.
6.
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
Sellner L, Bruggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, et al.
Bone Marrow Transplant . 2016 Dec; 52(4):544-551. PMID: 27941777
Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD)...
7.
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
Edelmann J, Tausch E, Landau D, Robrecht S, Bahlo J, Fischer K, et al.
Leukemia . 2016 Dec; 31(3):734-738. PMID: 27909343
No abstract available.
8.
Polymerase Chain Reaction Analysis of t(14;18) Junctional Regions in B-Cell Lymphomas
Kneba M, Eick S, Willigeroth S, Bolz I, Herbst H, Pott C, et al.
Leuk Lymphoma . 2016 Jul; 3(2):109-17. PMID: 27457296
The polymerase chain reaction (PCR) procedure was used for rapid and highly specific amplification of the t(14;18) bcl-2/JH DNA junctional regions in B-cell lymphomas. By using Taq-polymerase and relatively long...
9.
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
Hahn M, Bottcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, et al.
Bone Marrow Transplant . 2015 Jul; 50(10):1279-85. PMID: 26146810
To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL...
10.
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, et al.
Leukemia . 2014 May; 28(10):1988-92. PMID: 24798484
Unlabelled: Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative...